A Study to Evaluate the Safety and Dosimetry of 68Ga-labelled OncoFAP Derivatives in Solid Tumors

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 27, 2023

Primary Completion Date

October 21, 2024

Study Completion Date

October 21, 2024

Conditions

Breast CancerColorectal CancerOesophageal CancerPancreas Adenocarcinoma

Interventions

DRUG

[68Ga]Ga-OncoFAP administration

All patients will receive a single intravenous bolus administration of 250 MBq (225 - 275 MBq)

Trial Locations (5)

Istituto Clinico Humanitas, Rozzano

IRCCS San Raffaele, Milan

"IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori", Meldola

Azienda Ospedaliero Universitaria Pisana, Pisa

"Istituto Nazionale dei Tumori , Fondazione IRCCS"

All Listed Sponsors

lead

Philogen S.p.A.

INDUSTRY

NCT05784597 - A Study to Evaluate the Safety and Dosimetry of 68Ga-labelled OncoFAP Derivatives in Solid Tumors | Biotech Hunter | Biotech Hunter